Motavizumab (MEDI-524, Numax) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vírus Sincicial Respiratório Humano
/
Infecções por Vírus Respiratório Sincicial
/
Anticorpos Monoclonais
Limite:
Child, preschool
/
Humans
/
Infant
/
Newborn
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article